Skip to content

An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

Prospective Observational Study to Estimate the Genotype and Phenotype of Japanese Patients With X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR) - Prospective Observational Study to Estimate the Genotype and Phenotype of Japanese Patients With X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000044475
Enrollment
15
Registered
2021-06-20
Start date
2021-07-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-Linked Retinitis Pigmentosa

Interventions

None listed

Sponsors

Janssen Pharmaceutical K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Have RPGR-associated retinal dystrophy - Are able to give informed consent or assent, with the guidance of their parent/guardian where appropriate - Are able to undertake age-appropriate clinical assessments as specified in the protocol

Exclusion criteria

Exclusion criteria: - Are unable or unwilling to undertake consent or clinical testing - Participated in another research study and had intraocular surgery within 3 months of screening - Significant ophthalmologic diseases

Design outcomes

Primary

MeasureTime frame
Visual Function Up to Day 30 Visual function will be assessed using visual acuity. Retinal Structure Up to Day 30 Retinal structure will be assessed using spectral domain optical coherence tomography (SDOCT). Retinal Function Up to Day 30 Retinal function will be assessed using static visual field testing.

Countries

Japan

Contacts

Public ContactPersonnel Medical Information Center

Janssen Pharmaceutical K.K. Medical Information Center

DL-JANJP-JCO_TL_TSG_EMP@its.jnj.com0120-183-275

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026